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Identity 
Note: Intrachromosomal rearrangement. 
 
 
The fusion is product of a paracentric inversion of the long arm 
of chromosome 7. 
 
Clinics and pathology 
Disease  
Papillary Thyroid Carcinoma (PTC) 
Note: Papillary carcinoma is a well-differentiated 
tumor of thyroid follicular cell origin and is the most 
common thyroid malignancy, constituting about 80% 
of all cases. The only known etiologic factor for this 
type of tumor is exposure to ionizing radiation, 
although the history of radiation exposure is found in 
less than 10% of all cases. In the last year it became 
evident that alterations in the MAPK pathway, an 
intracellular cascade that regulates cell differentiation, 
proliferation and survival, are highly prevalent in 
papillary carcinomas. One type of genetic alterations 
found in these tumors involve the proto-oncogene RET, 
which encodes a receptor tyrosine kinase, and is a 
result of chromosomal rearrangements called RET/PTC 
(20-30% of cases). A small portion of cases presents 
with chromosomal rearrangements involving the 
NTRK gene, encoding another receptor tyrosine kinase. 
Point mutations of the RAS gene, another effector of 
the MAPK pathway, are found in about 15% of cases, 
and are particularly common in the follicular variant of 
papillary carcinoma. The most common alteration in 
these tumors is a point mutation of the serine-threonine 
kinase BRAF, yet another effector of the MAPK 
pathway (40% of cases). The point mutation typically 
involves nucleotide 1799 and leads to V600E 
substitution. The AKAP9-BRAF rearrangement is 
another mechanism of BRAF activation and is found in 
up to 11% of tumors associated with radiation 
exposure, but in less than 1% of sporadic tumors in the 
general population. 
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Cytogenetics 
Cytogenetics molecular 
Fluorescence in situ hybridization (FISH) with probes 
for the AKAP9 and BRAF gene can be used to detect 
the AKAP9-BRAF rearrangement, as it displays split of 
signals corresponding to both genes and fusion of 
signals on one chromosome. 
 
 
Reciprocal fusion detected by FISH with probes corresponding 
to the BRAF (red) and AKAP9 (green) genes. 
Genes involved and Proteins 
AKAP9 
Location: 7q21.2 
Protein 
AKAP9 belongs to a family of Protein A kinase (PKA) 
anchor proteins that bind the regulatory subunit of the 
PKA and target it to different locations within the cell. 
AKAP9, in particular, displays a centrosomal and 
Golgi compartmentalization. 
BRAF 
Location: 7q34 
Protein 
BRAF belongs to the family of RAF proteins which are 
effectors of the MAPK signaling cascade, a crucial 
pathway that regulates cell differentiation, proliferation 
and survival. Among 3 RAF isoforms (ARAF, BRAF, 
CRAF), BRAF displays the highest basal kinase 
activity. BRAF point mutations within the kinase 
domain of the protein occur in several tumor types 
including papillary thyroid carcinoma. 
 
 
Result of the chromosomal 
anomaly 
Hybride Gene 
Description 
Breakpoints occur within AKAP9 intron 8 and BRAF 
intron 8. The fusion transcript contains exon 1-8 of 
AKAP9 fused in frame with exon 9-18 of BRAF for a 
total open reading frame 4476 bp in size. 
Detection protocole 
AKAP9-BRAF rearrangement can be detected by RT-
PCR using primers flanking the breakpoint area 
(forward: 5'-AGCAAGAACAGTTGATTTTGGA-3'; 
reverse: 5'-GCAGACAAACCTGTGGTTGA-3') with 
the expected product of 181 bp. Amplify for 35 cycles 
(94C 5 min, 55C 1 min, 72C 1 min 20 sec). 
 
 
Scheme of the AKAP9-BRAF fusion. Arrows indicate 
breakpoints within both genes. 
Fusion protein 
Description 
The AKAP9-BRAF fusion protein contains the N-
terminal portion of AKAP9 (1087 aa) and the C-
terminal part of BRAF (386 aa) for a total protein size 
of 1473 aa (MW: 172 kDa). In the fusion protein, 
AKAP9 lacks the region responsible for binding to the 
regulatory subunit of PKA and BRAF lacks the auto-
inhibitory N-terminal portion of the protein and 
maintain intact the C-terminal tyrosine kinase domain. 
Oncogenesis 
The functioning of AKAP9-BRAF as an oncogene has 
been demonstrated by in vitro kinase assay and in vivo 
tumorigenesis assay. The oncogenic mechanism is 
probably due to the loss of the auto-inhibitory portion 
of BRAF in the fusion protein and fusion of the kinase 
domain of BRAF to the active promoter of AKAP9, 
resulting in constitutive activation of the BRAF 
tyrosine kinase and of the MAPK pathway. 
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